Compositions and methods for treatment of metastatic cancer
AssigneeAlexzander A. Asea
InventorAlexzander A. Asea
Life of this patent
Estimating the term…
Abstract
Disclosed are methods and compositions for treating cancer that involved an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of Hsp-27.
Claims102
A method of treating a subject with metastatic cancer or at risk of developing metastatic cancer, said method comprising administering to said subject with metastatic cancer or at risk of developing a metastatic cancer a pharmaceutically effective amount of a composition comprising an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of heat shock protein-27 (Hsp-27) using ribonucleic acid interference (RNAi) technology.
A method of treating a subject with cancer, comprising administering to said subject with cancer a pharmaceutically effective amount of a composition comprising an isolated dsRNA molecule that inhibits the expression of Hsp-27 and a synergistically effective amount of a platinum-containing chemotherapeutic agent.
A method of treating a subject with cancer, said method comprising administering to said subject with cancer a pharmaceutically effective amount of a composition comprising an isolated dsRNA molecule that inhibits the expression of Hsp-27 and a synergistically effective amount of a topoisomerase 1 inhibitor.
A method of reducing the chemotoxicity of a chemotherapeutic agent, said method comprising administering to a subject with cancer a pharmaceutically effective amount of a composition comprising an isolated dsRNA molecule that inhibits the expression of Hsp-27 concurrently with or prior to administration of a synergistically effective amount of said chemotherapeutic agent.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27, a length of from 19 to 28 consecutive nucleotides and a synergistically effective amount of a platinum-containing chemotherapeutic agent, wherein one strand of said dsRNA comprises SEQ ID NO:3.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27, and a synergistically effective amount of a topoisomerase 1 inhibitor, wherein one strand of said dsRNA comprises SEQ ID NO:
- 3.
A method of treating a patient with cancer or at risk of developing cancer without the use of a preliminary test, comprising administering to said patient with cancer or at risk of developing cancer a pharmaceutically effective amount of a composition comprising stem cells capable of differentiating into CD8+ T lymphocytes and a pharmaceutically effective amount of a composition comprising an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of HSP-27, wherein said dsRNA is administered to said stem cells capable of differentiating into CD8+ T lymphocytes thereby increasing the ability of said stem cells capable of differentiating into CD8+ T lymphocytes to recognize tumor-specific antigens and kill cancer cells, and wherein said patient is treated.
A method of treating a patient with cancer or at risk of developing cancer without the use of a preliminary test, comprising administering to a patient with cancer or at risk of developing cancer a pharmaceutically effective amount of a composition comprising autologous CD8+ T lymphocytes, wherein said lymphocytes have been contacted with isolated double stranded ribonucleic acid (dsRNA) molecules that inhibits the expression of HSP-27.
A method of inducing an immune response in a patient with a chemoresistant cancer without the use of a preliminary test, said method comprising administering to a patient with a chemoresistant cancer a pharmaceutically effective amount of CD8+ cells or stem cells capable of differentiating into CD8+ cells, wherein said CD8+ cells or stem cells have been contacted with a composition comprising an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of HSP-27.
A method of preventing the onset of cancer in a patient at risk for development of cancer without the use of a preliminary test, said method comprising administering to said patient a pharmaceutically effective amount of CD8+ cells or stem cells capable of differentiating into CD8+ cells, wherein said CD8+ cells or stem cells have been contacted with a composition comprising an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of HSP-27.
A pharmaceutical composition for inducing an immune response in a patient with cancer without the use of a preliminary test, said composition comprising stem cells capable of differentiating into CD8+ T lymphocytes and an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of HSP-27.
A pharmaceutical composition for inducing an immune response in a patient with cancer without the use of a preliminary test, said composition comprising a CD8+ T lymphocytes and an isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of HSP-27.
An isolated double stranded ribonucleic acid (dsRNA) molecule that inhibits the expression of a target gene, said dsRNA comprising two strands wherein a first strand has a length from 19 to 28 consecutive nucleotides and is substantially identical to a sequence in said target gene and wherein a second strand is substantially complementary to said first strand, and a binding moiety that binds a 3′ end of said first strand to a 5′ end of said second strand, wherein one strand of said dsRNA comprises SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, or SEQ ID NO:
- 11.
An isolated DNA molecule that encodes an RNA that inhibits the expression of Hsp27, wherein said DNA comprises SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, or SEQ ID NO:
- 10.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27 using ribonucleic acid interference (RNAi) technology, and a synergistically effective amount of a platinum-containing chemotherapeutic agent, wherein one strand of said dsRNA comprises SEQ ID NO:5.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27 using ribonucleic acid interference (RNAi) technology, and a synergistically effective amount of a platinum-containing chemotherapeutic agent, wherein one strand of said dsRNA comprises SEQ ID NO:7.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27 using ribonucleic acid interference (RNAi) technology, and a synergistically effective amount of a platinum-containing chemotherapeutic agent, wherein one strand of said dsRNA comprises SEQ ID NO:9.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27 using ribonucleic acid interference (RNAi) technology, and a synergistically effective amount of a platinum-containing chemotherapeutic agent, wherein one strand of said dsRNA comprises SEQ ID NO:11.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27 using ribonucleic acid interference (RNAi) technology, and a synergistically effective amount of a topoisomerase 1 inhibitor, wherein one strand of said dsRNA comprises SEQ ID NO:5.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27 using ribonucleic acid interference (RNAi) technology, and a synergistically effective amount of a topoisomerase 1 inhibitor, wherein one strand of said dsRNA comprises SEQ ID NO:7.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27 using ribonucleic acid interference (RNAi) technology, and a synergistically effective amount of a topoisomerase 1 inhibitor, wherein one strand of said dsRNA comprises SEQ ID NO:9.
A composition comprising an isolated dsRNA molecule with a length of 19 to 28 consecutive nucleotides, which inhibits the expression of Hsp-27 using ribonucleic acid interference (RNAi) technology, and a synergistically effective amount of a topoisomerase 1 inhibitor, wherein one strand of said dsRNA comprises SEQ ID NO:11.
Dependencies are inferred from the claim text.